登录

LAVA获得辉瑞700万美元投资,启动癌症候选药物PF-08046052临床开发

Lava gets $7M from Pfizer as trial for cancer drug advances

seekingalpha 2024-03-05 23:28 翻译由动脉网AI生成,点击反馈

可切换为仅中文


PM Images LAVA Therapeutics (NASDAQ:LVTX) announced Tuesday that Pfizer (PFE) had reached a key milestone in its clinical program for cancer candidate PF-08046052, leading to a $7M payment to the Dutch biotech as the first milestone payment in a collaboration between the two firms. “We are very pleased with the initiation of clinical development by Pfizer of PF-08046052,” CEO Stephen Hurly remarked.

PM Images LAVA Therapeutics(纳斯达克:LVTX)周二宣布,辉瑞(Pfizer)在其癌症候选人PF-08046052的临床计划中达到了一个关键的里程碑,导致向荷兰生物技术公司支付700万美元,这是两家公司合作的第一笔里程碑付款。首席执行官斯蒂芬·赫尔利(StephenHurly)表示:“我们非常高兴辉瑞公司开始临床开发PF-08046052。”。

“The initiation of the Phase 1 study for PF-08046052 marks the third asset utilizing LAVA’s Gammabody platform to enter the clinic,” he added. PF-08046052 is currently undergoing a Phase 1 trial as part of a licensing deal Pfizer (PFE) unit Seagen and LAVA reached in September 2022. According to its terms, LVTX was eligible for $50M upfront and up to ~$650M in milestone payments and royalties on potential sales.

他补充道:“PF-08046052的第一阶段研究的启动标志着利用LAVA的Gammabody平台进入诊所的第三项资产。”。PF-08046052目前正在进行第一阶段试验,作为2022年9月达成的辉瑞(PFE)旗下Seagen and LAVA许可协议的一部分。根据其条款,LVTX有资格获得5000万美元的预付款,以及高达约6.5亿美元的里程碑付款和潜在销售的版税。

More on LAVA Therapeutics LAVA stock rises on clinical trial collaboration with Merck Seeking Alpha’s Quant Rating on LAVA Therapeutics Historical earnings data for LAVA Therapeutics Financial information for LAVA Therapeutics .

更多关于LAVA Therapeutics的信息LAVA股票在临床试验中与默克公司合作,寻求Alpha对LAVA Therapeutics的定量评级LAVA Therapeutics的历史收益数据LAVA Therapeutics的财务信息。

推荐阅读

16周减重近10斤,辉瑞优化口服GLP-1给药配方

车维维 2024-07-12 17:37

辉瑞正推进每日一次GLP-1口服减肥药Danuglipron的研发

格隆汇 2024-07-11 18:53

每日一次,辉瑞推进口服GLP-1受体激动剂Danuglipron进入关键临床

businesswire 2024-07-11 16:45

seekingalpha

412篇

最近内容 查看更多

2024年迄今为止表现最好的10只生物技术股

2024-03-07

Creative Medical股价上涨18%,脆性1型糖尿病候选疗法获授予孤儿药称号

2024-03-06

Cyclacel Pharmaceuticals获得290万美元的研发税收抵免

2024-03-06

相关公司查看更多

Lava Therapeutics

双特异性抗体平台研发商

立即沟通

pfizer

药物研发商

立即沟通

产业链接查看更多